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Abstract
Emerging and re-emerging zoonotic diseases represent a public health challenge of international concern.
They include a large group of neglected tropical diseases (NTDs), many of which are of zoonotic nature.
Coronavirus disease 2019 (COVID-19), another emerging zoonotic disease, has just increased the stakes
exponentially. Most NTDs are subject to the impact of some of the very same human-related activities
triggering other emerging and re-emerging diseases, including COVID-19, severe acute respiratory syndrome
(SARS), bird flu and swine flu. It is conceivable that COVID-19 will exacerbate the NTDs, as it will divert much
needed financial and human resources. There is considerable concern that recent progress achieved with
control and elimination efforts will be reverted. Future potential strategies will need to reconsider the
determinants of health in NTDs in order to galvanize efforts and come up with a comprehensive, well
defined programme that will set the stage for an effective multi-sectorial approach. In this Commentary, we
propose areas of potential synergies between the COVID-19 pandemic control efforts, other health and non-
health sector initiatives and NTD control and elimination programmes.
Keywords: COVID-19, Emerging and re-emerging diseases, Multi-sectorial approaches, Neglected tropical
diseases, Zoonotic diseases
Background
Humanity faces a series of public and global health is-
sues. For instance, there is a wide range of emerging and
re-emerging zoonotic diseases, which affect a large num-
ber of individuals worldwide [1]. Hence, these diseases
should be an important component of the current public
health agenda, as they represent a serious public health
threat. Yet, this is not the case. Coronavirus disease 2019
(COVID-19), another emerging zoonosis [2], has just
increased the stakes exponentially [3]. The emergence of
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), the causative agent of COVID-19, is thought to
have originated from a bat reservoir. It is one of seven
coronaviruses known to infect humans.
Emerging and re-emerging diseases share a number of
determinant factors, one of which is particularly critical:
the impact of human activities on the environment [4].
Anthropogenic climate change is the most prominent
[5]. Yet, other determinants, such as armed conflicts and
war, changing land-use patterns, migration, unprece-
dented levels of transferring people and goods, and so-
cial inequity are known to pose major threats to human
health and well-being [6, 7]. The gap between the
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“haves” and “have-not” is increasing even within the new
developing economies. Vulnerable populations through-
out the world, such as ethnic minorities, not only have
less access to health care but are also disproportionally
affected by a wide range of neglected tropical diseases
(NTDs) [8, 9]. COVID-19 is clearly illustrating the im-
portance of tackling these determinants, as even the lar-
gest economies in the world, including the United States
of America, the People’s Republic of China and coun-
tries in Europe are not spared the consequences.
NTDs comprise an important group of bacterial, para-
sitic and viral diseases, many of which are of zoonotic
nature. Yet, as their name suggests, they continue to be
neglected by most of the affected countries’ health
agendas. Throughout the world, impoverished popula-
tions are heavily burdened with NTDs and often lack ac-
cess to primary health services [10]. The NTDs that
affect people living in vulnerable conditions create social
and financial burdens, which threaten the individual and
their communities [10]. In spite of notable progress in
controlling or even eliminating some NTDs (e.g. dracun-
culiasis, human African trypanosomiasis, lymphatic filar-
iasis and onchocerciasis), their importance in terms of
disease burden remains considerable [11, 12]. Import-
antly though, NTDs remain for the most part under-
funded and efforts to combat them rely on the good will
of the private sector and philanthropy. For example, on-
chocerciasis elimination in the Americas relied on a suc-
cessful partnership involving The Carter Center, Merck
and endemic countries, among other partners, and the
local communities [12]. COVID-19 threatens hard won
gains in NTD control and elimination efforts.
We are just beginning to appreciate the enormous
economic impact COVID-19 is having across the world.
It is conceivable that the economic crisis will drag mil-
lions of yet more people into poverty. It is not hard to
imagine what effect this will have on the large popula-
tions affected and at-risk of NTDs. Estimates of the
combined burden of the very first list comprising only
13 NTDs, i.e. 56.6 million disability-adjusted life years
(DALYs) exceeded that of malaria and tuberculosis and
even approached that of human immunodeficiency
virus/acquired immunodeficiency syndrome (HIV/AIDS)
[13]. According to 2015, estimates of the population at-
risk in the Western Pacific region (comprising 37 coun-
tries) stood at 200 million individuals for schistosomiasis
alone [9]. All of these countries now face the imminent
danger of the aftermath of COVID-19.
What do COVID-19 and NTDs have in common?
COVID-19 and most NTDs are characterized by com-
plex life cycles of the aetiological agents, which might in-
volve one or more hosts as well as one or more species
of vectors. Many NTDs are considered zoonosis because
they affect primarily animal hosts but can jump species
and affect humans, often with increased virulence and
pathogenicity. This jump is almost always related to hu-
man activities and their impact on the environment. The
list of NTDs is long [13, 14]. Out of the currently 20
NTDs listed by the World Health Organization (WHO)
[15], this Commentary highlights four zoonotic NTDs,
in order to illustrate prevention and control challenges,
which are likely to increase in face of the unfolding
COVID-19 pandemic [14, 16] (Table 1). The four se-
lected NTDs cause considerable morbidity, might even
lead to death and all have a significant economic impact
on the already impoverished populations they affect. We
believe that the economic impact of COVID-19 on these
populations will be severe and long lasting.
Schistosomiasis
WHO calls for an integrated control strategy to face up
to the challenge of 230 million people affected by this
infection worldwide, mostly in sub-Saharan Africa [17].
Snail control is an important component of the overall
control strategy, yet it has been found to pose consider-
able challenges. This is especially true in areas such as in
the People’s Republic of China where schistosomiasis
transmission persists as a zoonosis. Control and elimin-
ation in this country illustrates the complexity of some
of the issues. The number of infected people was esti-
mated to be 725,000 in 2005 [18]. Great progress has
been achieved since then with infection rates dropping
to < 0.001% in humans [19, 20]. In spite of continuous
efforts by the Ministry of Health and partners, focal
transmission persists in the lake region as a result of in-
fection in cattle and resilience of the snail intermediate
host posing a major risk for more than 30 million people
in the endemic areas of the People’s Republic of China
[21]. Unlike other schistosome species known to infect
humans, Schistosoma japonicum is a true zoonotic or-
ganism, with a range of mammalian reservoirs, rendering
control and elimination efforts difficult [22].
Cystic echinococcosis
Cystic echinococcosis continues to represent a public
health problem, affecting mostly disadvantaged people in
Africa, the Americas and Asia [23]. These infections rep-
resent a burden adding to the already precarious situ-
ation of those affected, mainly poor farmers and herders
throughout the endemic areas. Human incidence rates
can be as high as 50 per 100,000 person-years, and
prevalence levels as high as 5–10% in endemic regions.
In South America, prevalence rates in slaughterhouses
livestock can vary from 20 to 95%. For most countries in
Africa only scarce data exist, if at all [24]. Nevertheless,
it is conceivable that the combined burden posed by cys-
tic echinococcosis and other infectious diseases affecting
Ehrenberg et al. Infectious Diseases of Poverty            (2020) 9:86 Page 2 of 7
Ta
b
le
1
Si
m
ila
rit
ie
s
an
d
di
ffe
re
nc
es
be
tw
ee
n
C
O
VI
D
-1
9
an
d
fo
ur
se
le
ct
ed
zo
on
ot
ic
ne
gl
ec
te
d
tr
op
ic
al
di
se
as
es
G
en
er
al
as
pe
ct
s
C
O
VI
D
-1
9
Sc
hi
st
os
om
ia
si
s
C
ys
tic
ec
hi
no
co
cc
os
is
Le
is
hm
an
ia
si
s
H
um
an
A
fri
ca
n
tr
yp
an
os
om
ia
si
s
A
et
io
lo
g
ic
al
ag
en
t
SA
RS
-C
oV
-2
Sc
hi
st
os
om
a
sp
p.
Ec
hi
no
co
cc
us
sp
p.
Le
ish
m
an
ia
sp
p.
Tr
yp
an
os
om
a
sp
p.
Tr
an
sm
is
si
on
ro
ut
e
•
A
ni
m
al
-t
o-
hu
m
an
•
H
um
an
-t
o-
hu
m
an
•
H
um
an
-t
o-
sn
ai
l-t
o-
hu
m
an
(m
ig
ht
in
vo
lv
e
an
ot
he
r
ho
st
,e
.g
.w
at
er
bu
ffa
lo
)
•
D
og
-t
o-
sh
ee
p-
to
-d
og
(h
um
an
s
as
ac
ci
de
nt
al
or
ab
er
ra
nt
in
te
rm
ed
i-
at
e
ho
st
s)
•
D
iff
er
en
t
an
im
al
s
ac
t
as
ei
th
er
de
fin
iti
ve
or
in
te
rm
ed
ia
te
ho
st
•
H
um
an
-t
o-
in
se
ct
ve
ct
or
-t
o-
hu
m
an
,o
th
er
m
am
m
al
s
(e
.g
.
do
gs
)
ca
n
ac
t
as
ho
st
•
H
um
an
-t
o-
in
se
ct
ve
ct
or
-t
o-
hu
m
an
,
oc
ca
si
on
al
ly
an
ot
he
r
m
am
m
al
(e
.g
.
w
ild
un
gu
la
te
s)
ac
ts
as
re
se
rv
oi
rs
Pr
ev
en
ti
on
•
A
vo
id
cl
os
e
co
nt
ac
t/
cl
os
e
co
nf
in
em
en
t
w
ith
sy
lv
at
ic
an
im
al
re
se
rv
oi
r
•
So
ci
al
di
st
an
ci
ng
•
H
an
d
hy
gi
en
e
•
A
vo
id
cr
ow
de
d
pl
ac
es
•
En
vi
ro
nm
en
ta
ld
is
in
fe
ct
io
n
•
Fa
ce
m
as
ks
•
Pe
rs
on
al
pr
ot
ec
tiv
e
eq
ui
pm
en
t
fo
r
he
al
th
ca
re
pe
rs
on
ne
l
•
A
vo
id
co
nt
ac
t
w
ith
fre
sh
-
w
at
er
th
at
m
ay
be
in
fe
st
ed
w
ith
sc
hi
st
os
om
e
pa
ra
si
te
s
•
A
vo
id
co
nt
ac
t
w
ith
fa
ec
al
m
at
te
r
of
w
ild
an
im
al
s
an
d
do
gs
•
H
an
d
hy
gi
en
e
af
te
r
ha
nd
lin
g
do
gs
•
U
se
of
in
se
ct
re
pe
lle
nt
,
in
se
ct
ic
id
es
an
d
be
d
ne
ts
•
M
in
im
iz
e
co
nt
ac
t
w
ith
ve
ct
or
(i.
e.
ts
et
se
fli
es
)
M
ai
n
co
nt
ro
l
st
ra
te
g
ie
s
•
Ph
ys
ic
al
di
st
an
ci
ng
(in
di
vi
du
al
/s
ch
oo
l/
w
or
kp
la
ce
cl
os
ur
es
/b
or
de
r
cl
os
ur
es
)
•
C
as
e
is
ol
at
io
n
•
C
on
ta
ct
tr
ac
in
g
•
O
ve
ra
ll
ep
id
em
ic
al
er
t
an
d
re
sp
on
se
m
ea
su
re
s
in
cl
ud
in
g
ris
k
co
m
m
un
ic
at
io
n
•
H
ea
lth
ed
uc
at
io
n
•
M
as
s
dr
ug
ad
m
in
is
tr
at
io
n
•
Sn
ai
lc
on
tr
ol
st
ra
te
gi
es
•
Im
pr
ov
ed
sa
ni
ta
tio
n
•
H
ea
lth
ed
uc
at
io
n
•
Li
m
it
th
e
in
te
ra
ct
io
ns
be
tw
ee
n
do
gs
an
d
ro
de
nt
po
pu
la
tio
ns
•
Pr
ev
en
t
do
gs
fro
m
fe
ed
in
g
on
th
e
ca
rc
as
se
s
of
in
fe
ct
ed
sh
ee
p
•
C
on
tr
ol
st
ra
y
do
g
po
pu
la
tio
ns
•
Ea
rly
di
ag
no
si
s
an
d
tr
ea
tm
en
t,
es
pe
ci
al
ly
m
or
e
ef
fic
ac
io
us
dr
ug
s
•
Ve
ct
or
co
nt
ro
l
•
C
on
tr
ol
st
ra
y
do
g
po
pu
la
tio
ns
•
En
vi
ro
nm
en
ta
lm
an
ag
em
en
t
•
A
ct
iv
e
an
d
pa
ss
iv
e
ca
se
de
te
ct
io
n
an
d
tr
ea
tm
en
t
of
co
nf
irm
ed
ca
se
s
•
Ve
ct
or
co
nt
ro
ls
tr
at
eg
ie
s
•
M
an
ag
em
en
t
of
th
e
an
im
al
re
se
rv
oi
r
•
En
vi
ro
nm
en
ta
lm
an
ag
em
en
t
C
ha
lle
ng
es
•
Va
cc
in
e
an
d
dr
ug
s
de
ve
lo
pm
en
t
•
Im
pr
ov
em
en
t
in
an
im
al
he
al
th
su
rv
ei
lla
nc
e
an
d
fu
rt
he
r
w
ild
lif
e
st
ud
ie
s
to
in
cr
ea
se
kn
ow
le
dg
e
on
an
im
al
re
se
rv
oi
r
•
Va
cc
in
es
•
Im
pr
ov
em
en
t
in
an
im
al
he
al
th
su
rv
ei
lla
nc
e
fo
cu
se
d
on
ca
tt
le
•
Sn
ai
lc
on
tr
ol
•
Va
cc
in
e
an
d
ne
w
di
ag
no
st
ic
m
et
ho
ds
•
N
ew
dr
ug
s
•
Im
pr
ov
ed
co
lla
bo
ra
tio
n
w
ith
an
im
al
he
al
th
se
ct
or
to
im
pr
ov
e
su
rv
ei
lla
nc
e
(e
.g
.s
la
ug
ht
er
ho
us
es
)
•
Va
cc
in
e
•
N
ew
dr
ug
s
•
Im
pr
ov
ed
re
se
rv
oi
r
an
d
ve
ct
or
co
nt
ro
lm
et
ho
ds
•
Im
pr
ov
ed
co
nt
ro
lo
f
st
ra
y
do
g
po
pu
la
tio
ns
w
he
re
vi
sc
er
al
le
is
hm
an
ia
si
s
is
m
os
t
pr
ev
al
en
t
•
Ti
m
el
y
di
ag
no
si
s
to
av
oi
d
hi
gh
ou
t-
of
-p
oc
ke
t
he
al
th
ex
pe
nd
itu
re
s
•
Va
cc
in
e
•
D
ev
el
op
m
en
t
of
ne
w
co
nt
ro
l
m
et
ho
ds
•
Su
rv
ei
lla
nc
e
st
ra
te
gi
es
CO
VI
D
-1
9
C
or
on
av
iru
s
di
se
as
e
20
19
,S
A
RS
-C
oV
-2
Se
ve
re
ac
ut
e
re
sp
ira
to
ry
sy
nd
ro
m
e
co
ro
na
vi
ru
s
2
Ehrenberg et al. Infectious Diseases of Poverty            (2020) 9:86 Page 3 of 7
the very same population groups represents a major
challenge to their health status and socioeconomic de-
velopment. The paucity of effective tools to treat and
prevent these infections represent a persistent obstacle
illustrating the lack of interest by the relevant sectors in
the development of new and efficacious drugs for many
NTDs. It also highlights the lack of strategies, which
could tap on the involvement of other sectors and key
stakeholders behind a public health problem the deter-
minants of which clearly reach well beyond the human
health sector.
Leishmaniasis
Comprised of multiple species of causative agents, leish-
maniasis are among the top ten NTDs with more than
12 million infected people throughout the Americas, Af-
rica, Asia and the Middle East [25]. This complex in-
cludes a particularly worrisome species for its morbidity,
visceral leishmaniasis (VL), with 200,000 to 400,000 new
cases per year worldwide, and an estimate of 20,000 to
40,000 deaths per year [26].
In 2017, 20,792 out of 22,145 new cases (94%) re-
ported to WHO occurred in just seven countries;
namely, Brazil, Ethiopia, India, Kenya, Somalia, South
Sudan and Sudan [25, 27]. VL is prevalent in 12 coun-
tries in the Americas with 59,769 new cases reported
from 2001 to 2017. Brazil accounts for 96% (57,582) of
these cases [28]. The incidence rate of VL increased
from 1990 to 2018 by 52.9% in this country alone with
an even higher increase in children under the age of 1
year [28].
An additional challenge to effective control of this dis-
ease is canine visceral leishmaniasis (CVL), which consti-
tutes a public health problem in some of the endemic
countries. Cases of CVL are known to precede human
cases of the disease, because dogs act as a reservoir. CVL
plays an important role in the maintenance of transmis-
sion levels and the spread of the disease, particularly in
urban areas [27, 29].
Human African trypanosomiasis
Human African trypanosomiasis control programmes
throughout Africa have been successful, recording a de-
crease of cases during the period 2001–2010 of 73.4%
[30]. Yet, in spite of these impressive gains, delayed diag-
nosis of human African trypanosomiasis reported to
have caused 93% of the affected households to experi-
ence an increase in financial expenditure (ranging from
USD 60–170) in seeking treatment. To cover these out-
of-pocket health expenditures, 81.5% of the affected fam-
ilies experienced difficulties in raising money for treat-
ment resorting to various ways of raising it such as
selling agricultural produce, seeking assistance from
family and friends, selling/leasing of family assets, seek-
ing credit and/or using personal savings [31].
It is to be expected that COVID-19 will greatly con-
tribute to the impoverishment of these populations ser-
iously jeopardizing decades’ long programmatic gains
leading to a resurgence of human African
trypanosomiasis.
Challenges and recommendations: a case for a multi-
sectoral strategy
We are currently facing one of the most serious public
health crises in decades, the COVID-19 pandemic [32].
Most NTDs are subject to the impact of some of the
very same human-related activities triggering other
emerging and re-emerging diseases, such as COVID-19,
SARS, bird flu and swine flu. The exact life cycle of
COVID-19’s agent remains elusive to date [32]. The rea-
son these epidemic-prone diseases attract more attention
than the NTDs is that they can affect all, poor and rich,
with extreme dire consequences in a short period of
time. People can die within days of showing first symp-
toms. Just mentioning SARS or COVID-19 elicits a ner-
vous response even from the financial sector. Economic
losses have been consequently enormous. The key differ-
ence is NTDs affect primarily marginalized communities
in low- and middle-income countries (LMICs), mainly
rural and deprived urban communities. Economic losses,
though significant, tend to be more selective in NTDs,
affecting primarily the poor and medium income popu-
lations. While there is a frantic race among countries
and pharmaceutical companies in COVID-19 for vac-
cines, drugs, diagnostics and protective gear, NTDs are
not perceived as a lucrative market by the very same sec-
tors hampering the development of diagnostics, drugs
and vaccines.
COVID-19 could very well last for months, perhaps
years. Unless we raise the profile of the NTDs, while the
human population is highly sensitized to a public health
crisis the likes of COVID-19, we might not get another
opportunity to leverage on the raised awareness of emer-
ging and re-emerging zoonotic diseases.
Health services and disease surveillance will need to
undergo profound changes in order to find more effect-
ive ways of coping with emerging and re-emerging dis-
eases in the future, zoonosis among these. The failure of
most countries to respond adequately to COVID-19
makes a clear case for significant transformation of our
systems. The NTD community would be well advised to
jump on board. Integration of health and care services
(e.g. group- and disease-specific models) [33] will need
to be seriously considered in a post-COVID-19 world. It
might also offer several potential venues to tackle mor-
bidity in some NTDs. This issue deserves special atten-
tion, as it remains to be seen whether current integrated
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Table 3 Examples of where other health and non-health sectors (private, public and not-for-profit) could synergize NTD efforts
Sector Opportunities for synergies
Veterinary • Disease surveillance (clinical and laboratory)
• Field related logistics
• One Health initiative
Policy • Legislation
• Assigning and/or increasing programme budgets
• Streamlining financial flows to support effective supply chains
• Implement strategies to promote economic development of affected populations (e.g. micro enterprises,
revolving funds, etc.)
Economic • Cost and feasibility studies
Marketing • Tap on private sector expertise and adapt to use in health programmes
Communication • Adapt private and public sector strategies
Pharmaceutical • In conjunction with national academia and other organizations (e.g. Drugs for Neglected Diseases initiative
(DNDi)), support development of new drugs and diagnostics
Environmental • Programmes targeting sustainable environment protection actions to prevent severe environmental
degradation in NTD areas
Information Technology (IT) • Integrated information systems
• Access to inter-sectoral data bases
• Geographic information systems
• New surveillance systems
Transportation • Private companies (e.g. beverage sector) support public health interventions
Malaria, tuberculosis and HIV/AIDS • Include NTDs in a repackaging of public health interventions
• Malaria, tuberculosis and HIV/AIDS benefit from integrated synergies
• NTDs benefit from high media profile of the three big ones
Agriculture • Encourage community development in NTD endemic areas by
• enabling local produce and self-sufficiency;
• organic farming;
• assistance in placing produce in markets; and
• One Health initiative
Education • Access to rural and marginalized population groups
• Sensitizing in health and environment topics
• Incorporating health into educational messages and curricula
Anthropology • Provide tools to enable integration of local cultural patterns into public health programmes
Psychology • Integrated mental health programmes relying on ethical and culturally sensitive tools supporting vulnerable
populations
Development • Poverty alleviation programmes
• Capacity building in income generating activities
Table 2 Examples of where COVID-19 could synergize NTD efforts
Fields in mitigation Opportunities for synergies with NTD control and elimination programmes
Overall surveillance capabilities strengthened in COVID-19
including surveillance sentinel sites
May improve NTD surveillance
Political stakeholders Leverage for increased involvement in NTDs
Private stakeholders Leverage for increased involvement in NTDs
Risk communications developed for epidemic prone diseases May support greater community involvement and behavioural
changes in NTDs
Media information dissemination Piggybacking opportunity for NTDs
IT capabilities strengthened in COVID-19 Piggybacking opportunity for NTDS
Field logistics Piggybacking opportunity for NTDs
COVID-19 Coronavirus disease 2019, NTDs Neglected tropical diseases, IT Information Technology
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health care models could be extrapolated to NTDs in
settings of LMICs.
An example of how non-health sector programme ac-
tivities could be articulated with elements of NTD hel-
minth control programme activities is described in a
comprehensive analysis conducted in 2015. The analysis
renders an interesting scenario, which should be further
explored [9]. The One Health initiative is a movement
to forge co-equal, all inclusive collaborations between
physicians, osteopathic physicians, veterinarians, den-
tists, nurses and other scientific-health and environmen-
tally related disciplines. However, it needs to ensure that
other relevant sectors are included in the discussions of
methodologies, definition of indicators and in the actual
implementation of multicentre pilot studies to determine
feasibility of multi-sectoral strategies. Given the unique-
ness of each setting, meaning countries and continents,
potential synergies with COVID-19 public health inter-
ventions (Table 2) and other sectors (Table 3) agendas
would need to be tested and adapted to each particular
social-ecological setting.
Conclusions
We believe that COVID-19 will exacerbate the NTD
situation, as it will divert much needed financial and hu-
man resources. One might even anticipate a reversal in
progress achieved in some of the NTD control and elim-
ination efforts, similar to what is predicted for child and
maternal health, malaria, tuberculosis and HIV/AIDS
[34, 35]. Public health services are being stretched to
their limits by COVID-19 and will continue to be so for
some time to come. Other public health programmes
will most likely suffer the consequences across the
board. This will force the medical and the political es-
tablishments to make some extremely tough choices.
We conjecture that COVID-19 will push a large propor-
tion of the human population into poverty, even extreme
poverty. To the NTD community, while we do face this
rather dire scenario, it is imperative that we find alterna-
tive strategies if we want to retain the gains of NTD con-
trol and elimination programmes.
Future potential strategies will need to reconsider the de-
terminants of health in NTDs in order to galvanize efforts
and come up with comprehensive, well defined programmes
that will set the stage for a multi-sectorial approach involv-
ing the medical, animal and human, developmental, envir-
onmental, agricultural, education, economy, anthropology,
communications, public, private sectors, bilateral agencies
and information technology sectors.
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